Galectin Therapeutics traded at $2.98 this Friday February 27th, decreasing $0.16 or 5.10 percent since the previous trading session. Looking back, over the last four weeks, Galectin Therapeutics lost 3.25 percent. Over the last 12 months, its price rose by 89.81 percent. Looking ahead, we forecast Galectin Therapeutics to be priced at 2.88 by the end of this quarter and at 2.62 in one year, according to Trading Economics global macro models projections and analysts expectations.
Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.